Skip to content

PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics

PASTRAMI : Patient-specific Statistics for Microstructure-augmented Connectomics

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07527949
Acronym
PASTRAMI
Enrollment
100
Registered
2026-04-14
Start date
2026-09-01
Completion date
2030-09-01
Last updated
2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Magnetic Resonance Imaging (MRI), Traumatic Brain Injury

Brief summary

Traumatic brain injury (TBI) represent a major public health issue, accounting for approximately 1.5 million hospital admissions annually across the European Union and 160,000 cases in France. They are a significant cause of mortality and disability, with serious consequences for patients and their families. Predicting functional outcomes remains complex due to the heterogeneity of brain injuries, whether primary or secondary, as well as the mechanisms involved, particularly neuroinflammation. This difficulty is particularly pronounced for moderate to severe TBI, for which current predictive tools are still limited. The PASTRAMI project proposes to utilise diffusion magnetic resonance imaging (MRI) to identify biomarkers associated with axonal lesions in the white matter. This technique enables the analysis of brain microstructure and the reconstruction of neural connections (connectome), thereby offering innovative prospects for improving the prediction of functional recovery. This is a prospective, multicentre, interventional study involving 100 patients aged between 18 and 60 years with moderate to severe traumatic brain injury. The primary objective is to assess the prognostic value of brain microstructural measures at baseline, by correlating them with the GOSE functional score at 1 year. Secondary objectives include the analysis of mortality, functional outcome, quality of life, and early physiological factors influencing progression. Patients will undergo a standard MRI scan supplemented with additional sequences for prognostic purposes, without any change to their therapeutic management. The associated risks are minimal and relate primarily to the MRI scan. No immediate individual benefit is expected, but the results could improve our understanding of brain lesions and optimise future management. The total duration of the study is 48 months. The expected outcomes include better characterisation of lesions and improved predictive tools, contributing to more appropriate clinical decisions.

Interventions

OTHERMeasures of brain microstructure

Measures of brain microstructure

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Aged 18 to 60 2. Admitted for moderate to severe non-penetrating head injury (with a Glasgow Coma Scale score ≤ 12) 3. On mechanical ventilation and under continuous sedation 4. Enrolled in a social security program 5. Whose family has been informed and has signed a voluntary, informed, written consent form

Exclusion criteria

1. History of head trauma, stroke, or neurodegenerative diseases 2. A decision to limit active treatment has already been made 3. Quadriplegia 4. Contraindications to MRI 5. Protected individuals (adults under legal protection \[judicial protection, guardianship, conservatorship\], individuals deprived of liberty, pregnant women \[self-reported\], breastfeeding women, and minors).

Design outcomes

Primary

MeasureTime frameDescription
GOSE score (Glasgow Outcome Scale Extended) [between 1 and 8 (higher score mean a better outcome)]1 yearCorrelation between the GOSE score at 1 year and measures of brain microstructure at baseline
Measures of brain microstructurebaselineCorrelation between the GOSE score at 1 year and measures of brain microstructure at baseline

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026